Kinnate Biopharma Cash from Financing (TTM) Insights

Kinnate Biopharma Inc (DELISTED) (KNTE:DL)

2.65 0.00 (0.00%) USD | NASDAQ | Apr 03, 16:00

Cash from Financing (TTM) Chart

Historical Cash from Financing (TTM) Data

View and export this data back to 2020. Upgrade now.

Date	Value
December 31, 2023	-7.808M
September 30, 2023	-7.615M
June 30, 2023	-7.482M
March 31, 2023	-8.081M
December 31, 2022	1.16M
September 30, 2022	1.524M
June 30, 2022	1.527M

Date	Value
March 31, 2022	36.36M
December 31, 2021	36.24M
September 30, 2021	289.41M
June 30, 2021	386.38M
March 31, 2021	350.91M
December 31, 2020	350.90M

Cash From Financing Definition

Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.

Read full definition.

Cash from Financing (TTM) Range, Past 5 Years

-8.081M

Minimum

Mar 2023

386.38M

Maximum

Jun 2021

109.49M

Average

1.527M

Median

Jun 2022

Cash from Financing (TTM) Benchmarks